CTBO (Cantabio Pharmaceuticals) EPS (Basic): $-230.37 (TTM As of Dec. 2018)


What is Cantabio Pharmaceuticals EPS (Basic)?

Cantabio Pharmaceuticals CTBO EPS (Basic) is $-230.37 as of Dec. 2018.

Cantabio Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Dec. 2018 was $19.63. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2018 was $-230.37.

Cantabio Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2018 was $19.63. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2018 was $-230.37.

Cantabio Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2018 was $-19.24. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2018 was -275.89.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cantabio Pharmaceuticals  (OTCPK:CTBO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cantabio Pharmaceuticals EPS (Basic) Related Terms

Cantabio Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals EPS (Basic) Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
EPS (Basic)
Get a 7-Day Free Trial -20.00 50.00 -200.00 -200.00 -350.00

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -100.00 -150.00 -50.00 -50.00 19.63

Cantabio Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cantabio Pharmaceuticals's Basic EPS for the fiscal year that ended in Mar. 2018 is calculated as

Basic EPS (A: Mar. 2018 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.012-0)/0.006
=-335.33

Cantabio Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2018 is calculated as

Basic EPS (Q: Dec. 2018 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0.343-0)/0.017
=20.18

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-230.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-230.37 mean?
Cantabio Pharmaceuticals (CTBO) has a EPS (Basic) of $-230.37 as of Dec. 2018. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' EPS (Basic) too high?
Cantabio Pharmaceuticals' current EPS (Basic) is $-230.37.
How does Cantabio Pharmaceuticals' EPS (Basic) compare to TNTY and ETNI?
Cantabio Pharmaceuticals' EPS (Basic) of $-230.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current EPS (Basic) is $-230.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current EPS (Basic) of $-230.37. The current EPS (Basic) is $-230.37. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current EPS (Basic) is $-230.37 as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.